Peter T. Chapman

4.8k total citations
82 papers, 3.2k citations indexed

About

Peter T. Chapman is a scholar working on Nephrology, Rheumatology and Surgery. According to data from OpenAlex, Peter T. Chapman has authored 82 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Nephrology, 29 papers in Rheumatology and 21 papers in Surgery. Recurrent topics in Peter T. Chapman's work include Gout, Hyperuricemia, Uric Acid (27 papers), Case Reports on Hematomas (17 papers) and Rheumatoid Arthritis Research and Therapies (15 papers). Peter T. Chapman is often cited by papers focused on Gout, Hyperuricemia, Uric Acid (27 papers), Case Reports on Hematomas (17 papers) and Rheumatoid Arthritis Research and Therapies (15 papers). Peter T. Chapman collaborates with scholars based in New Zealand, United Kingdom and United States. Peter T. Chapman's co-authors include Lisa K. Stamp, J O'donnell, Murray L. Barclay, Christopher Frampton, Dorian O. Haskard, A. Michael Peters, Andrew Harrison, Jill Drake, François Jamar and Jill James and has published in prestigious journals such as The Journal of Immunology, Gut and Radiology.

In The Last Decade

Peter T. Chapman

81 papers receiving 3.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter T. Chapman New Zealand 35 1.2k 971 766 515 480 82 3.2k
Atsuo Taniguchi Japan 37 2.5k 2.0× 524 0.5× 593 0.8× 590 1.1× 542 1.1× 195 4.1k
John Boletis Greece 28 771 0.6× 644 0.7× 420 0.5× 202 0.4× 726 1.5× 154 3.0k
Debashish Danda India 29 1.1k 0.9× 548 0.6× 501 0.7× 418 0.8× 627 1.3× 180 3.1k
Marc A. Seelen Netherlands 36 599 0.5× 996 1.0× 583 0.8× 554 1.1× 1.9k 4.0× 107 3.8k
Manuela Födinger Austria 32 1.3k 1.0× 244 0.3× 517 0.7× 444 0.9× 916 1.9× 117 3.0k
E Imbasciati Italy 28 543 0.4× 1.8k 1.9× 361 0.5× 291 0.6× 481 1.0× 94 2.9k
Keith E. Holley United States 38 795 0.6× 1.4k 1.5× 609 0.8× 744 1.4× 386 0.8× 85 4.3k
Ramnath Misra India 34 2.1k 1.6× 385 0.4× 350 0.5× 736 1.4× 1.2k 2.5× 208 3.9k
Seza Özen Türkiye 30 730 0.6× 790 0.8× 710 0.9× 1.5k 2.9× 744 1.6× 196 3.6k
Marion Haubitz Germany 40 720 0.6× 1.0k 1.1× 464 0.6× 1.3k 2.6× 768 1.6× 119 4.7k

Countries citing papers authored by Peter T. Chapman

Since Specialization
Citations

This map shows the geographic impact of Peter T. Chapman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter T. Chapman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter T. Chapman more than expected).

Fields of papers citing papers by Peter T. Chapman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter T. Chapman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter T. Chapman. The network helps show where Peter T. Chapman may publish in the future.

Co-authorship network of co-authors of Peter T. Chapman

This figure shows the co-authorship network connecting the top 25 collaborators of Peter T. Chapman. A scholar is included among the top collaborators of Peter T. Chapman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter T. Chapman. Peter T. Chapman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Stamp, Lisa K. & Peter T. Chapman. (2020). Allopurinol hypersensitivity: Pathogenesis and prevention. Best Practice & Research Clinical Rheumatology. 34(4). 101501–101501. 44 indexed citations
3.
Stamp, Lisa K., et al.. (2019). The challenges of managing gout in primary care: Results of a best-practice audit. Australian Journal of General Practice. 48(9). 631–637. 11 indexed citations
4.
Stamp, Lisa K., Peter T. Chapman, Murray L. Barclay, et al.. (2018). How much allopurinol does it take to get to target urate? Comparison of actual dose with creatinine clearance-based dose. Arthritis Research & Therapy. 20(1). 255–255. 14 indexed citations
5.
Wright, Sarah, et al.. (2017). Management of Gout in a Hospital Setting: A Lost Opportunity. The Journal of Rheumatology. 44(10). 1493–1498. 9 indexed citations
6.
Stamp, Lisa K., Peter T. Chapman, Murray L. Barclay, et al.. (2017). A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Annals of the Rheumatic Diseases. 76(9). 1522–1528. 104 indexed citations
7.
Stamp, Lisa K., Peter T. Chapman, Lutz Beckert, et al.. (2015). Association between environmental exposures and granulomatosis with polyangiitis in Canterbury, New Zealand. Arthritis Research & Therapy. 17(1). 333–333. 14 indexed citations
8.
Stamp, Lisa K. & Peter T. Chapman. (2014). Urate-Lowering Therapy: Current Options and Future Prospects for Elderly Patients with Gout. Drugs & Aging. 31(11). 777–786. 22 indexed citations
9.
Chapman, Peter T., et al.. (2012). Wegener's granulomatosis: treatment and survival characteristics in a high‐prevalence southern hemisphere region. Internal Medicine Journal. 42(4). e23–6. 7 indexed citations
10.
Stamp, Lisa K., J O'donnell, Peter T. Chapman, et al.. (2010). Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long‐term methotrexate therapy. Arthritis & Rheumatism. 62(2). 359–368. 68 indexed citations
11.
Stamp, Lisa K., J O'donnell, Peter T. Chapman, et al.. (2009). Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long‐term methotrexate treatment. Arthritis & Rheumatism. 60(8). 2248–2256. 81 indexed citations
12.
Stamp, Lisa K., et al.. (2008). Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis & Rheumatism. 58(11). 3299–3308. 152 indexed citations
13.
Savage, Ruth, et al.. (2006). Pneumonitis associated with leflunomide: a profile of New Zealand and Australian reports. Internal Medicine Journal. 36(3). 162–169. 40 indexed citations
14.
Stamp, Lisa K., et al.. (2006). Gout in renal transplant recipients. Nephrology. 11(4). 367–371. 26 indexed citations
15.
Möller, Peter, et al.. (2005). Adult‐onset inflammatory myopathy: North Canterbury experience 1989–2001. Internal Medicine Journal. 35(3). 170–173. 32 indexed citations
16.
Taylor, Peter C., A. Michael Peters, Ewa Paleolog, et al.. (2000). Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritis. Arthritis & Rheumatism. 43(1). 38–47. 330 indexed citations
17.
Harrison, Andrew, Claire J. Stocker, Peter T. Chapman, et al.. (1997). Expression of vascular cell adhesion molecule-1 by vascular endothelial cells in immune and nonimmune inflammatory reactions in the skin. The Journal of Immunology. 159(9). 4546–4554. 31 indexed citations
18.
Jamar, François, Peter T. Chapman, D. Manicourt, et al.. (1997). A comparison between 111In-anti-E-selectin mAb and 99Tcm-labelled human non-specific immunoglobulin in radionuclide imaging of rheumatoid arthritis.. British Journal of Radiology. 70(833). 473–481. 43 indexed citations
19.
Chapman, Peter T., François Jamar, Andrew Harrison, et al.. (1994). Noninvasive imaging of e‐selectin expression by activated endothelium in urate crystal–induced arthritis. Arthritis & Rheumatism. 37(12). 1752–1756. 33 indexed citations
20.
Chapman, Peter T., et al.. (1992). A mini-stirrer for preparing antigen/adjuvant emulsions. Transactions of the Royal Society of Tropical Medicine and Hygiene. 86(3). 333–333. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Atsuo Taniguchi Breakdown of academic impact, for papers by John Boletis Breakdown of academic impact, for papers by Debashish Danda Breakdown of academic impact, for papers by Marc A. Seelen Breakdown of academic impact, for papers by Manuela Födinger Breakdown of academic impact, for papers by E Imbasciati Breakdown of academic impact, for papers by Keith E. Holley Breakdown of academic impact, for papers by Ramnath Misra Breakdown of academic impact, for papers by Seza Özen Breakdown of academic impact, for papers by Marion Haubitz
Rankless by CCL
2026